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ABSTRACT
Objective
To provide insight into current practice in planning for, and acknowledging, the presence of learning 
and clustering effects, by treating centre and surgeon, when developing randomised surgical trials.
Study design and setting
Complexities associated with delivering surgical interventions, such as clustering effects, by centre or 
surgeon, and surgical learning, should be considered at trial design. Main trial publications within the 
wider literature under-report these considerations
Funded applications, within a four year period, from a leading UK funding body were searched. Data 
were extracted on considerations for learning and clustering effects and the driver, funder or 
applicant, behind these. 
Results
Fifty trials were eligible. Managing learning through establishing pre-defined centre and surgeon 
credentials was common. One planned exploratory analysis of learning within centre, and two within 
surgeon. Clustering, by site and surgeon, was often managed through stratifying randomisation, with 
81% and 60% respectively also planning to subsequently adjust analysis. One-third of responses to 
referees contained funder led changes accounting for learning and/or clustering. 
Conclusion
Whilst underreported in main publications, tThis review indicates that researchers do consider impact 
of learning and clustering, by centres and surgeon, during trial development. Furthermore, the funder 
is identified as a potential driver of considerations.
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MANUSCRIPT TEXT
1. INTRODUCTION
Randomised controlled trials (RCTs) are recognised as providing the highest level of evidence, second 
only to systematic reviews of such trials.[1] The need for surgical randomised trials is well recognised 
[2, 3], and this has led to a push for growth in recent years. [3, 4] Leading research organisations are 
supporting this growth through establishing a number of initiatives and research objectives, ultimately 
aiming to improve of the global surgical evidence base. [5-10] One such initiative, set up by the United 
Kingdom’s (UK) leading publically funded health research body, the National Institute of Health 
Research (NIHR), aimed to increase the volume of high quality research, across surgical disciplines, on 
the effectiveness, delivery and organisation of surgery and surgical services. [7] More recently, the 
NIHR Unit on Global Surgery was formed, [10] to establish research hubs in low and middle income 
countries across the world.  With the conduct of surgical trials growing in number, and becoming more 
geographically dispersed, ensuring that they are designed and analysed appropriately is essential to 
support clinical decision-making. 
The assessment of surgical interventions is complex, due to the interacting components, such as the 
intervention itself, surgical expertise and pre and post-operative care. [11] When designing 
randomised surgical trials, it is important to consider the potential existence and impact of surgical 
learning curves, where the surgical expertise increases throughout the course of the trial. Another 
important consideration is clustering. Clustering occurs when patient outcomes within centre, surgical 
team or surgeon, are more similar than those from patients treated by different centres, teams or 
surgeons. 
Recognition and management of learning curves and clustering within clinical trials is recommended 
[12], and may have increased relevance within the surgical field, dependent upon the interventions 
being investigated and their routine use. [11-15].
 It is important therefore to consider the significance of these aspects at trial outset, to ensure that 
the resulting trial is conducted and analysed with the highest possible rigour. However, main trial 
publications often do not report deliberations and justifications for selected approaches. [16] To 
overcome this limitation, we investigate a cohort of applications for randomised surgical trials funded 
by the NIHR.  This review will determine how learning and clustering by centre and surgeon are 
managed at the design stage and accounted for in the intended analysis, and provide insight into who 
drives the decision-making for these: the funder, guided by reviewers and panel members, or the 
researcher. We aim to provide a more detailed insight into current practice with regards to planning 
for, and acknowledging, the presence of learning and clustering at the design stage. 
2. MATERIALS AND METHODS
2.1. Included studies
We sought to examine trials that had received funding from the NIHR from two funding streams, the 
Health Technology Assessment (HTA) programme [17] and Efficacy and Mechanism Evaluation (EME) 
[18] programme, in the UK, from 2012 to 2016. Research projects funded by these programmes are 
either in response to a commissioning brief or an open investigator led call. These funding streams 
were chosen as they are known to endorse high quality research and were actively funding surgical 
research during this time [7]. An initial unpublished search indicated that this period would provide a 
reasonable cohort size to establish current practice. All randomised trials where the patient pathway 
involves a surgical intervention of any kind were eligible for inclusion.  
2.2. Documents for review
The NIHR HTA and EME funding process involves a two stage, peer reviewed application process. 
Protocols and the commissioning brief (where applicable) were obtained from the open access NIHR 
Journals Library [19] The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) provided 
documentation not publically available: project descriptions and applicant responses to reviewer 
comments. 
2.3. Data extraction
A previously developed extraction form [16] was adapted for use on this cohort by EJC and CG and 
approved by GB, JAC, and JMB, see Supplement A1. The extraction form was piloted on five 
applications initially and, as no further amendments were required, subsequently used on all 
applications by a single assessor (EJC). Data extracted were quality checked through double data 
extraction by a second reviewer (ARH) on 10% of all applications. A discrepancy rate was specified a 
priori such that if greater than 5% across all fields then a further 10% would be checked until the rate 
was below 5%. Discrepancies were jointly reviewed and agreement reached, if agreement could not 
be reached then a third reviewer (CG) was consulted.
Details on trial design, randomisation stratification, sample size adjustment, pre-determined centre 
and surgeon credentials, outcomes, and planned statistical analyses that adjusted for centre and 
surgeon were collected. 
2.4. Statistical Analysis
Quantitative items were summarised using descriptive statistics; no formal statistical comparisons 
were undertaken. Data was analysed using SAS 9.3; SAS Institute Inc., Cary, NC, USA. Open textual 
data items; were categorised using NVivo qualitative data analysis software (QSR International Pty Ltd. 
Version 10, 2012). A confidentiality agreement with the NIHR Evaluation, Trials and Studies 
Coordinating Centre was signed prior to receiving the documentation. The raw data cannot therefore 
be made publicly available and text extracts have been anonymised by removal of treatment or 
condition identifiers. Deleted text is denoted by […] and the addition of words or replaced words is 
denoted by [words] to aid understanding.
3. RESULTS
3.1. Cohort details
The NETSCC compiled a report listing all surgery randomised controlled trials funded by the HTA and 
EME funding streams within the eligible period.  Sixty potentially eligible studies were identified, of 
which 49 (82%) met the eligibility criteria following further central screening (Figure A1). 
3.2. Double data extraction
Five articles were randomly selected from the eligible studies for double data extraction. Of 155 
variables checked, two discrepancies were identified (1.3% error rate). 
3.3. Cohort summary
The majority of the applications were funded by the HTA (n=44/49, 89%) and had start dates from 
2014 onwards (n=37/49, 76%); see Table 1.  
Documents for review consisted of commissioning briefs (n=15/49, 31%), project descriptions 
(n=40/49, 82%), applicant responses to board and peer review comments (n=40/49, 82%) and 
protocols (n=42/49, 86%). Either the protocol or project description was available for all applications; 
see Table 1. 
One application consisted of two distinct RCTs, herein treated as separate trials.
Item Category n N n/N%
One 48 49 98%Number of RCTs in 
application Two 1 49 2%
HTA 44 49 90%Funder 
EME 5 49 10%
East 1 49 2%Lead institution region
East Midlands 4 49 8%
Item Category n N n/N%
London 10 49 20%
North East 7 49 14%
North West 2 49 4%
Scotland 10 49 20%
South East 3 49 6%
South West 4 49 8%
Wales 2 49 4%
West Midlands 4 49 8%
Yorkshire and the Humber 2 49 4%
2012 3 49 6%
2013 9 49 18%
2014 26 49 53%
2015 3 49 6%
2016 1 49 2%
Trial start year
2017 7 49 14%
Commissioning brief 15 49 31%
Project description 40 49 82%
Responses to board and peer review 
comments
40 49 82%
Source documents 
available1
Protocol 42 49 86%
1 Documents available: All applications with project description also had responses to board and peer review comments (n=40). A 
minimum of either the protocol or the project description and responses to board and peer review comments were available for all 
applications.  
Table 1: Cohort summary
3.4. Trial demographics
Trials were primarily two-armed (n=45/50, 90%) and of a parallel design (n=49/50, 98%). Eight did not 
use a pilot or feasibility study (n=8/50, 16%) [20]. In 11 studies (n=11/50, 22%), surgery was not the 
intervention of interest and delivered as part of the patient pathway. Where surgery was the 
intervention of interest (n=39/50, 78%), 21 compared against surgery, for example minimal access vs. 
open surgery (n=21/39, 54%). The remaining eighteen compared surgery against a non-surgical 
comparator (medical comparator e.g. injection vs. surgery: n=7/39, other e.g. active monitoring and 
surgery vs. active monitoring only: n=11/39) (see Table A1, Table 2). 
3.5. Recruitment and randomisation
Patients were the randomisation unit in all trials and primarily allocated to equal groups (n=48/50, 
96%). The majority stratified randomisation (n=46/50, 92%). In trials comparing two surgeries, there 
were no expertise-based designs [21]. Table A2 provides more detail. 
Almost all studies were multi-centre (n=49/50, 98%), with over half stratifying by centre (n=28/49, 
57%). Of the 21 that did not stratify by centre, only one provided justification which related to concern 
over allocation concealment:
“To reduce the risk of the randomisation sequence being predictable we will not stratify by centre, 
which in addition to using randomly selected permuted blocks, will make the allocation sequence 
unpredictable for individual trial centres.” 
Twenty-two trials had multiple surgeons within each centre, of which eight stratified the 
randomisation accordingly (n=8/22, 36%). Two surgeon-stratified trials followed funder 
recommendation. 
“We have made a number of changes since the first application…randomisation will be stratified 
according to [stratification 1], [stratification 2], and according to consultant surgeon.”
In trials reported as multi-centre and multi-surgeon (n=21), two stratified for both centre and surgeon, 
eleven centre only, six surgeon only, and two stratified for neither.
Three trials were international, of which one stratified randomisation on randomised within a UK, or 
non UK, centre.
Table 2 provides more detail.
Stratified by centre Stratified by surgeon
Multi-
centre
Yes No Multi-
surgeon
Yes No
Nature of surgery 
delivered
Comparator
Number of 
trials in 
cohort
N n n/N% n n/N% N n n/N% n n/N%
Surgery Alternative surgical procedure 13 13 5 38% 8 62% 6 4 67% 2 33%As an intervention
Change to a component of the 
same procedure
6 5 4 80% 1 20% 6 3 50% 3 50%
Same procedure delivered at 
a different time point
2 2 1 50% 1 50% 0 0 . 0 .
Medical 7 7 5 71% 2 29% 2 0 . 2 100%
Other 11 11 5 45% 6 55% 3 0 . 3 100%
As part of patient pathway 11 11 8 73% 3 27% 5 1 20% 4 80%
Table 2: Stratification factors in multi-centre and multi-surgeon trials by intervention type
3.6. Surgeon and centre credentials
Centre and surgeon credentials, or inclusion criteria of those delivering the intervention, were 
provided in 41 (n=41/50, 82%) and 36 (n=36/50, 72%) trials, respectively (Table 3). Most common 
centre credentials were case volume (n=20) and required fields of expertise within centre (n=13). 
Examples of surgeon credentials were grade or experience (n=16) and study specific training (n=13).
Centre level Surgeon level
Centre credential provided 41 Surgeon credentials provided 36
    Case volume 20 (48%)     Level of job role 16 (44%)
    Fields of expertise within centre 13 (32%)     Study specific training 13 (36%)
    Experience required without definition 9 (22%)     Experience required without definition 8 (22%)
    Experience required with definition 8 (20%)     Oversight of supervision 7 (19%)
    Good recruiting reputation 8 (20%)     Prior number of cases 7 (19%)
    Experience required with definition 8 (20%)     Self assessed ability 7 (19%)
    Access to equipment required 7 (17%)     Equipoise 4 (11%)
    Centre to undertake trial specific training 2 (5%)     Known to be good recruiters 3 (8%)
    Demonstrated ability to participate 1 (2%)     Case volume 2 (6%)
    Interest expressed in specific treatment 1 (2%)     Local practice relevant 1 (3%)
    Prior number of cases required 1 (2%)
    Centre delivers one treatment only 1 (2%)
 Table 3: Centre and surgeon credentials
3.7. Trial outcomes related to learning and clustering
Forty-one applications explored outcomes that may reflect variability in centre or surgeon skill (82%, 
Table 4). Common outcomes were safety events (n=36); recovery from surgery (n=13) and operative 
time (n=6). 
Surgeon level outcomes were experience of surgeons in trial, established through qualitative methods 
(n=3); surgeon accuracy as a main trial outcome (n=1); and expertise (n=1), more specifically:
“The first [feasibility] phase will establish [words] and a measure of surgical expertise.”
Outcome
Relevant outcome reported 41
    Safety measures 36 (88%)
    Recovery from surgery time 13 (32%)
    Operative time 6 (15%)
    Patient satisfaction with surgery 5 (12%)
    Infection 4 (10%)
    Experience of surgeons in trial1 3 (7%)
    Surgeon accuracy 1 (2%)
    Surgeon expertise2 1 (2%)
1 Established using qualitative methods; 2 Feasibility outcome
Table 4: Outcomes
3.8. Statistical Considerations
3.8.1. Sample size calculation
There were No no examples of sample size adjustment for clustering at a centre level were identified. 
Three applications adjusted the sample size for surgeon using an intra class correlation coefficient 
(ICC) and a fourth chose not to adjust although provided justification:
“As this study is not evaluating surgery per-se, surgical experience is not a criterion for participation 
(all participants will be under the care of a consultant surgeon). In the context of [this] study, clustering 
by surgeon is not relevant to the sample size and can be ignored (on the basis that the intraclass 
correction is negligible”.
3.8.2. Exploratory analysis
Eight applications planned exploratory analysis considering differences by centre. Three analysed 
using descriptive statistics and three via a subgroup analysis: the first conducting a trial centre by 
treatment effect analysis, the second comparing outcomes between more and less experienced 
centres, and the third exploring trends within centres over time. A sensitivity analysis adjusting for 
centre effects was planned in one application. Learning within centre was described in another. 
“The effect of experience in [comparator intervention] at each recruitment centre will be studied to 
characterise the effect of the learning curve on clinical effectiveness, and also the effect on [standard 
intervention] outcomes.”
Exploratory analyses considering differences by surgeon were planned in seven applications, of which 
three also explored by centre. Two analysed descriptively by surgeon grade and four via subgroup 
analysis: one modelled the learning curve using outcomes operation time and complications as a proxy 
to measure the task efficiency of the surgeon, one planned to explore trends and changes over time 
between experienced and less experienced surgeons, one via a qualitative analysis and the final where 
patients were sampled for observations in theatre according to their treating surgeons’ grade. As with 
centre, one application planned a sensitivity analysis that adjusted for surgeon. 
3.8.3. Formal adjustment
Formal adjustment for multiple centre or surgeon effect was planned in 21 and 15 applications, 
respectively. Table 5 provides more detail. When formally adjusting for centre, nine planned to use a 
random effect and thirteen did not specify. Similarly, six planned to adjust for surgeon using a random 
effect and nine did not specify. Of the applications planning a formal adjustment, 17 (n=17/21, 81%) 
of applications adjusting for centre and nine (n=9/15, 60%) adjusting for surgeon did so in addition to 
stratifying randomisation by these variables.
The two applications that planned to stratify by both centre and surgeon (Table 3), also planned 
formally adjusting analysis by these factors. 
Centre Surgeon
n N n/N% n N n/N%
Adjustment made 21 49 43% 15 22 68%
Fixed 0 21 . 0 15 .
Random 9 21 43% 6 15 40%
Time varying 0 21 . 0 15 .
Approach to adjustment (type of effect)
Not specified 12 21 57% 9 15 60%
Randomisation stratified by and adjustment made Yes 17 21 81% 9 15 60%
Table 5: Planned statistical Formal statistical adjustments through analysis  made in multi-centre and multi-surgeon trials
3.9. Funder led considerations
3.9.1. Commissioning briefs
Of the fifteen commissioning briefs, one permitted single centre studies and one required a multi-
centre setting. No other brief gave guidance with respect to number of centres. Two briefs identified 
surgical learning considerations as an issue to address: the first indicating outcomes may be 
independent of surgeon grade and the second:
“Proposals should account for the possibility of a learning curve affecting the outcomes of [surgery].” 
3.9.2. Changes driven by funder 
Response to referee comments were available for 40 studies (n=40/49, 81.6%). Fourteen examples of 
change within twelve applications were identified. Funder concerns led to sample size adjustment for 
surgeon (n=3); randomisation balanced for surgeon (n=2) and centre (n=1); and improved 
generalisability by increasing the number of centres (n=3):
“The Board suggested that the team should consider the addition of a second centre to demonstrate 
generalisability and help with recruitment.” 
In one application, funders requested applicants increase homogeneity in treatments and the 
applicants argued against this. 
“To ensure homogeneity in treatments we have consulted with our participating surgeons [and] the 
National […] Registry and agreed to specify the use of a CE marked [device…there are three main 
devices]. Surgical trials that specify a single type of [device] are notoriously difficult to conduct and we 
do not believe such a design could recruit surgeons, nor would the outputs be generalisable. “
Further considerations with regard to surgeon credentials (n=3) and the impact of surgeon equipoise 
on recruitment (n=1) were also funder driven. 
“The sample size has been increased from a total of [n] patients to a total of [1.4n] to take into account 
clustering of surgeon as per the feedback from the first stage.”
4. CONCLUSIONS
This review has investigated the decision-making behind intended design and analysis of 50 
randomised surgical trials funded by the NIHR EME and NIHR HTA programmes from 2012 to 2016. 
These results show frequent consideration of centres and surgeon impact during design, and these 
may be funder led, due to concerns around homogeneity or generalisability of results. This review 
provides a cross sectional insight into current practice of researchers, and expectations of reviewers 
and funders, during trial design within two streams of a major UK funder. [17, 18] 
The need for transparency around learning curves and clustering are highlighted within reporting of 
non-pharmacological interventions guidelines, [22, 23] and a review of the published literature 
identified a deficiency in adherence to these [16]. In contrast, this review identifies that considerations 
to manage learning and clustering are made, by both researchers and funders, during development of 
trials funded by a prestigious body. For example, 30% of multi-centre and 12% of multi-surgeon 
studies reported a statistical adjustment of these within published manuscripts. This was 423% and 
698% respectively in this cohort. When randomisation was stratified by centre or surgeon, this was 
accounted for in the analysis in 30% of multi-centre and 40% of multi-surgeon trials in the published 
manuscripts, as oppose to 81% and 60% in this cohort. In drawing this comparison it is important to 
differentiate between the intended audiences. The detail required for a funding application, assessed 
by clinicians and methodologists/statisticians, may exceed that required to communicate results to a 
clinical audience. This demonstrates benefit in exploring unpublished trial documentation to 
understand approaches to trial design and analysis and highlights the need for improvements to 
transparent reporting.
The cohort included successful applications to the NIHR 2012 call for Applied Health in Surgery. [7] 
This call recognised the need to increase research-based evidence in surgery. Applications were 
invited that evaluated technology-driven implanted or implantable medical devices, surgical 
procedures or surgical services. As a clinical trial is typically a major financial investment, [24] 
applicants need to assure funders that their proposal is important, well designed and demonstrates 
scientific value to add to the current evidence base. Each application undergoes a peer review process, 
where ‘experts’ critically review the trial to ensure standards are met in terms of design, quality, 
feasibility, acceptability and importance of the topic. [17, 18] A strength of this review is the insight 
into the designs proposed to funders, and impact of feedback on subsequently funded studies. 
Whilst the degree of learning and clustering will vary trial-to-trial, many interventions require surgical 
skill in their delivery regardless of whether or not the surgery is the intervention of interest. The impact 
of of any ppotential imbalance inof delivery on will have on  comparing the interventioncomparing 
interventions should be considered at trial outset routinely. Early and careful consideration will ensure 
that procedures are standardised as completely as possible such that, in severe cases, the trial team 
can alleviate any doubts about homogeneity raised by the medical community should the trial results 
be questioned. [12] . These results indicate funder awareness of this early consideration, with one of 
the two examples of balancing randomisation surgeon following recommendation being in a trial 
where surgery was not the intervention of interest. 
When interpreting these results, it is important to consider the limitations of this review. First, only 
successful applications could be included due to confidentiality constraints. It is therefore not possible 
to determine whether the management of learning and clustering contributes to the success of the 
application. However, given that the application process consists of iterations whereby peer reviewers 
are able to request that researchers address paucities in their application, it is unlikely that a promising 
application, lacking in the appropriate considerations, would be deemed unsuitable for funding 
outright. More likely, researchers would be given the opportunity to make these considerations during 
this iteration process. Second, as part of this iterative review, it is possible that additional discussions 
at the funder board meetings did not make it in to the comments fed back to applicants. This could 
mean that funders raised these issues more frequently than this review suggests. Third, , due to the 
nature of the grant application process, the funder impact observed may be in part due to an increased 
awareness of the reviewers involved. Fourth, this work has focussed on a single funding body that 
primarily supports UK based research. However, trials supported span a wide range of surgical 
specialties and health care conditions and results from this review will be generalisable to other 
funding bodies with a similar peer review process.  
Fundamental to trial design and analysis is understanding the objectives. While considerations relating 
to clustering and learning effects are not widely reported in main trial publications, these results 
indicate both funders and researchers consider these aspects in order to address a specific research 
question. Such issues may have varying relevance depending on the overall design of the trial. A very 
pragmatic study may deliberately include surgeons and centres of all types and have less emphasis on 
expertise and learning, whereas the delivery of the intervention in more explanatory studies is critical 
and requires consideration during design and analysis. Another approach to overcoming these issues 
is to provide quality assurance of the intervention. Early work to develop methods to achieve this have 
been developed and it is expected that this will expand in the future. [25] Furthermore, these results 
provide insight into the promising role of the funder as a driver to improving the, long criticised, 
surgical evidence base. The funder, who has influence over whether or not and how studies are carried 
out and has been suggested as a driver for improving the quality of research during the period of 
growth for surgical trials [3], can play a valuable role in ensuring that future trials do not have the 
same shortfalls as those in the past.
What is new?
 This review investigates successful funding applications comprising a wide variety of trials, 
both by surgical discipline and by geographic location, by a leading UK funder. 
 This review is timely as it comprises applications rewarded following a call by this funder 
recognising a need for an increase in evidence based surgical research.
 A novel assessment of the decision making behind intended design and analysis with respect 
to the management of surgical learning and clustering is presented. Results indicate that while 
these considerations are under reported in main trial publications, funders and researchers 
alike appear to be aware of the need to manage these aspects at the trial design stage. 
 Insight into the promising role of the funder as a driver to improving the, long criticised, 
surgical evidence base is provided.
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MANUSCRIPT TEXT
1. INTRODUCTION
Randomised controlled trials (RCTs) are recognised as providing the highest level of evidence, second 
only to systematic reviews of such trials.[1] The need for surgical randomised trials is well recognised 
[2, 3], and this has led to a push for growth in recent years. [3, 4] Leading research organisations are 
supporting this growth through establishing a number of initiatives and research objectives, ultimately 
aiming to improve of the global surgical evidence base. [5-10] One such initiative, set up by the United 
Kingdom’s (UK) leading publically funded health research body, the National Institute of Health 
Research (NIHR), aimed to increase the volume of high quality research, across surgical disciplines, on 
the effectiveness, delivery and organisation of surgery and surgical services. [7] More recently, the 
NIHR Unit on Global Surgery was formed, [10] to establish research hubs in low and middle income 
countries across the world.  With the conduct of surgical trials growing in number, and becoming more 
geographically dispersed, ensuring that they are designed and analysed appropriately is essential to 
support clinical decision-making. 
The assessment of surgical interventions is complex, due to the interacting components, such as the 
intervention itself, surgical expertise and pre and post-operative care. [11] When designing 
randomised surgical trials, it is important to consider the potential existence and impact of surgical 
learning curves, where the surgical expertise increases throughout the course of the trial. Another 
important consideration is clustering. Clustering occurs when patient outcomes within centre, surgical 
team or surgeon, are more similar than those from patients treated by different centres, teams or 
surgeons. 
Recognition and management of learning curves and clustering within clinical trials is recommended 
[12], and may have increased relevance within the surgical field, dependent upon the interventions 
being investigated and their routine use. [11-15].
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 It is important therefore to consider the significance of these aspects at trial outset, to ensure that 
the resulting trial is conducted and analysed with the highest possible rigour. However, main trial 
publications often do not report deliberations and justifications for selected approaches. [16] To 
overcome this limitation, we investigate a cohort of applications for randomised surgical trials funded 
by the NIHR.  This review will determine how learning and clustering by centre and surgeon are 
managed at the design stage and accounted for in the intended analysis, and provide insight into who 
drives the decision-making for these: the funder, guided by reviewers and panel members, or the 
researcher. We aim to provide a more detailed insight into current practice with regards to planning 
for, and acknowledging, the presence of learning and clustering at the design stage. 
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2. MATERIALS AND METHODS
2.1. Included studies
We sought to examine trials that had received funding from the NIHR from two funding streams, the 
Health Technology Assessment (HTA) programme [17] and Efficacy and Mechanism Evaluation (EME) 
[18] programme, in the UK, from 2012 to 2016. Research projects funded by these programmes are 
either in response to a commissioning brief or an open investigator led call. These funding streams 
were chosen as they are known to endorse high quality research and were actively funding surgical 
research during this time [7]. An initial unpublished search indicated that this period would provide a 
reasonable cohort size to establish current practice. All randomised trials where the patient pathway 
involves a surgical intervention of any kind were eligible for inclusion.  
2.2. Documents for review
The NIHR HTA and EME funding process involves a two stage, peer reviewed application process. 
Protocols and the commissioning brief (where applicable) were obtained from the open access NIHR 
Journals Library [19] The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) provided 
documentation not publically available: project descriptions and applicant responses to reviewer 
comments. 
2.3. Data extraction
A previously developed extraction form [16] was adapted for use on this cohort by EJC and CG and 
approved by GB, JAC, and JMB, see Supplement A1. The extraction form was piloted on five 
applications initially and, as no further amendments were required, subsequently used on all 
applications by a single assessor (EJC). Data extracted were quality checked through double data 
extraction by a second reviewer (ARH) on 10% of all applications. A discrepancy rate was specified a 
priori such that if greater than 5% across all fields then a further 10% would be checked until the rate 
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was below 5%. Discrepancies were jointly reviewed and agreement reached, if agreement could not 
be reached then a third reviewer (CG) was consulted.
Details on trial design, randomisation stratification, sample size adjustment, pre-determined centre 
and surgeon credentials, outcomes, and planned statistical analyses that adjusted for centre and 
surgeon were collected. 
2.4. Statistical Analysis
Quantitative items were summarised using descriptive statistics; no formal statistical comparisons 
were undertaken. Data was analysed using SAS 9.3; SAS Institute Inc., Cary, NC, USA. Open textual 
data items; were categorised using NVivo qualitative data analysis software (QSR International Pty Ltd. 
Version 10, 2012). A confidentiality agreement with the NIHR Evaluation, Trials and Studies 
Coordinating Centre was signed prior to receiving the documentation. The raw data cannot therefore 
be made publicly available and text extracts have been anonymised by removal of treatment or 
condition identifiers. Deleted text is denoted by […] and the addition of words or replaced words is 
denoted by [words] to aid understanding.
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3. RESULTS
3.1. Cohort details
The NETSCC compiled a report listing all surgery randomised controlled trials funded by the HTA and 
EME funding streams within the eligible period.  Sixty potentially eligible studies were identified, of 
which 49 (82%) met the eligibility criteria following further central screening (Figure A1). 
3.2. Double data extraction
Five articles were randomly selected from the eligible studies for double data extraction. Of 155 
variables checked, two discrepancies were identified (1.3% error rate). 
3.3. Cohort summary
The majority of the applications were funded by the HTA (n=44/49, 89%) and had start dates from 
2014 onwards (n=37/49, 76%); see Table 1.  
Documents for review consisted of commissioning briefs (n=15/49, 31%), project descriptions 
(n=40/49, 82%), applicant responses to board and peer review comments (n=40/49, 82%) and 
protocols (n=42/49, 86%). Either the protocol or project description was available for all applications; 
see Table 1. 
One application consisted of two distinct RCTs, herein treated as separate trials.
Item Category n N n/N%
One 48 49 98%Number of RCTs in 
application Two 1 49 2%
HTA 44 49 90%Funder 
EME 5 49 10%
East 1 49 2%Lead institution region
East Midlands 4 49 8%
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
Item Category n N n/N%
London 10 49 20%
North East 7 49 14%
North West 2 49 4%
Scotland 10 49 20%
South East 3 49 6%
South West 4 49 8%
Wales 2 49 4%
West Midlands 4 49 8%
Yorkshire and the Humber 2 49 4%
2012 3 49 6%
2013 9 49 18%
2014 26 49 53%
2015 3 49 6%
2016 1 49 2%
Trial start year
2017 7 49 14%
Commissioning brief 15 49 31%
Project description 40 49 82%
Responses to board and peer review 
comments
40 49 82%
Source documents 
available1
Protocol 42 49 86%
1 Documents available: All applications with project description also had responses to board and peer review comments (n=40). A 
minimum of either the protocol or the project description and responses to board and peer review comments were available for all 
applications.  
Table 1: Cohort summary
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3.4. Trial demographics
Trials were primarily two-armed (n=45/50, 90%) and of a parallel design (n=49/50, 98%). Eight did not 
use a pilot or feasibility study (n=8/50, 16%) [20]. In 11 studies (n=11/50, 22%), surgery was not the 
intervention of interest and delivered as part of the patient pathway. Where surgery was the 
intervention of interest (n=39/50, 78%), 21 compared against surgery, for example minimal access vs. 
open surgery (n=21/39, 54%). The remaining eighteen compared surgery against a non-surgical 
comparator (medical comparator e.g. injection vs. surgery: n=7/39, other e.g. active monitoring and 
surgery vs. active monitoring only: n=11/39) (see Table A1, Table 2). 
3.5. Recruitment and randomisation
Patients were the randomisation unit in all trials and primarily allocated to equal groups (n=48/50, 
96%). The majority stratified randomisation (n=46/50, 92%). In trials comparing two surgeries, there 
were no expertise-based designs [21]. Table A2 provides more detail. 
Almost all studies were multi-centre (n=49/50, 98%), with over half stratifying by centre (n=28/49, 
57%). Of the 21 that did not stratify by centre, only one provided justification which related to concern 
over allocation concealment:
“To reduce the risk of the randomisation sequence being predictable we will not stratify by centre, 
which in addition to using randomly selected permuted blocks, will make the allocation sequence 
unpredictable for individual trial centres.” 
Twenty-two trials had multiple surgeons within each centre, of which eight stratified the 
randomisation accordingly (n=8/22, 36%). Two surgeon-stratified trials followed funder 
recommendation. 
“We have made a number of changes since the first application…randomisation will be stratified 
according to [stratification 1], [stratification 2], and according to consultant surgeon.”
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In trials reported as multi-centre and multi-surgeon (n=21), two stratified for both centre and surgeon, 
eleven centre only, six surgeon only, and two stratified for neither.
Three trials were international, of which one stratified randomisation on randomised within a UK, or 
non UK, centre.
Table 2 provides more detail.
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Stratified by centre Stratified by surgeon
Multi-
centre
Yes No Multi-
surgeon
Yes No
Nature of surgery 
delivered
Comparator
Number of 
trials in 
cohort
N n n/N% n n/N% N n n/N% n n/N%
Surgery Alternative surgical procedure 13 13 5 38% 8 62% 6 4 67% 2 33%As an intervention
Change to a component of the 
same procedure
6 5 4 80% 1 20% 6 3 50% 3 50%
Same procedure delivered at 
a different time point
2 2 1 50% 1 50% 0 0 . 0 .
Medical 7 7 5 71% 2 29% 2 0 . 2 100%
Other 11 11 5 45% 6 55% 3 0 . 3 100%
As part of patient pathway 11 11 8 73% 3 27% 5 1 20% 4 80%
Table 2: Stratification factors in multi-centre and multi-surgeon trials by intervention type
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3.6. Surgeon and centre credentials
Centre and surgeon credentials, or inclusion criteria of those delivering the intervention, were 
provided in 41 (n=41/50, 82%) and 36 (n=36/50, 72%) trials, respectively (Table 3). Most common 
centre credentials were case volume (n=20) and required fields of expertise within centre (n=13). 
Examples of surgeon credentials were grade or experience (n=16) and study specific training (n=13).
Centre level Surgeon level
Centre credential provided 41 Surgeon credentials provided 36
    Case volume 20 (48%)     Level of job role 16 (44%)
    Fields of expertise within centre 13 (32%)     Study specific training 13 (36%)
    Experience required without definition 9 (22%)     Experience required without definition 8 (22%)
    Experience required with definition 8 (20%)     Oversight of supervision 7 (19%)
    Good recruiting reputation 8 (20%)     Prior number of cases 7 (19%)
    Experience required with definition 8 (20%)     Self assessed ability 7 (19%)
    Access to equipment required 7 (17%)     Equipoise 4 (11%)
    Centre to undertake trial specific training 2 (5%)     Known to be good recruiters 3 (8%)
    Demonstrated ability to participate 1 (2%)     Case volume 2 (6%)
    Interest expressed in specific treatment 1 (2%)     Local practice relevant 1 (3%)
    Prior number of cases required 1 (2%)
    Centre delivers one treatment only 1 (2%)
 Table 3: Centre and surgeon credentials
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3.7. Trial outcomes related to learning and clustering
Forty-one applications explored outcomes that may reflect variability in centre or surgeon skill (82%, 
Table 4). Common outcomes were safety events (n=36); recovery from surgery (n=13) and operative 
time (n=6). 
Surgeon level outcomes were experience of surgeons in trial, established through qualitative methods 
(n=3); surgeon accuracy as a main trial outcome (n=1); and expertise (n=1), more specifically:
“The first [feasibility] phase will establish [words] and a measure of surgical expertise.”
Outcome
Relevant outcome reported 41
    Safety measures 36 (88%)
    Recovery from surgery time 13 (32%)
    Operative time 6 (15%)
    Patient satisfaction with surgery 5 (12%)
    Infection 4 (10%)
    Experience of surgeons in trial1 3 (7%)
    Surgeon accuracy 1 (2%)
    Surgeon expertise2 1 (2%)
1 Established using qualitative methods; 2 Feasibility outcome
Table 4: Outcomes
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3.8. Statistical Considerations
3.8.1. Sample size calculation
There were no examples of sample size adjustment for clustering at a centre level. Three applications 
adjusted the sample size for surgeon using an intra class correlation coefficient (ICC) and a fourth 
chose not to adjust although provided justification:
“As this study is not evaluating surgery per-se, surgical experience is not a criterion for participation 
(all participants will be under the care of a consultant surgeon). In the context of [this] study, clustering 
by surgeon is not relevant to the sample size and can be ignored (on the basis that the intraclass 
correction is negligible”.
3.8.2. Exploratory analysis
Eight applications planned exploratory analysis considering differences by centre. Three analysed 
using descriptive statistics and three via a subgroup analysis: the first conducting a trial centre by 
treatment effect analysis, the second comparing outcomes between more and less experienced 
centres, and the third exploring trends within centres over time. A sensitivity analysis adjusting for 
centre effects was planned in one application. Learning within centre was described in another. 
“The effect of experience in [comparator intervention] at each recruitment centre will be studied to 
characterise the effect of the learning curve on clinical effectiveness, and also the effect on [standard 
intervention] outcomes.”
Exploratory analyses considering differences by surgeon were planned in seven applications, of which 
three also explored by centre. Two analysed descriptively by surgeon grade and four via subgroup 
analysis: one modelled the learning curve using outcomes operation time and complications as a proxy 
to measure the task efficiency of the surgeon, one planned to explore trends and changes over time 
between experienced and less experienced surgeons, one via a qualitative analysis and the final where 
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patients were sampled for observations in theatre according to their treating surgeons’ grade. As with 
centre, one application planned a sensitivity analysis that adjusted for surgeon. 
3.8.3. Formal adjustment
Formal adjustment for multiple centre or surgeon effect was planned in 21 and 15 applications, 
respectively. Table 5 provides more detail. When formally adjusting for centre, nine planned to use a 
random effect and thirteen did not specify. Similarly, six planned to adjust for surgeon using a random 
effect and nine did not specify. Of the applications planning a formal adjustment, 17 (n=17/21, 81%) 
of applications adjusting for centre and nine (n=9/15, 60%) adjusting for surgeon did so in addition to 
stratifying randomisation by these variables.
The two applications that planned to stratify by both centre and surgeon (Table 3), also planned 
formally adjusting analysis by these factors. 
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Centre Surgeon
n N n/N% n N n/N%
Adjustment made 21 49 43% 15 22 68%
Fixed 0 21 . 0 15 .
Random 9 21 43% 6 15 40%
Time varying 0 21 . 0 15 .
Approach to adjustment (type of effect)
Not specified 12 21 57% 9 15 60%
Randomisation stratified by and adjustment made Yes 17 21 81% 9 15 60%
Table 5: Planned statistical  adjustments through analysis in multi-centre and multi-surgeon trials
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3.9. Funder led considerations
3.9.1. Commissioning briefs
Of the fifteen commissioning briefs, one permitted single centre studies and one required a multi-
centre setting. No other brief gave guidance with respect to number of centres. Two briefs identified 
surgical learning considerations as an issue to address: the first indicating outcomes may be 
independent of surgeon grade and the second:
“Proposals should account for the possibility of a learning curve affecting the outcomes of [surgery].” 
3.9.2. Changes driven by funder 
Response to referee comments were available for 40 studies (n=40/49, 81.6%). Fourteen examples of 
change within twelve applications were identified. Funder concerns led to sample size adjustment for 
surgeon (n=3); randomisation balanced for surgeon (n=2) and centre (n=1); and improved 
generalisability by increasing the number of centres (n=3):
“The Board suggested that the team should consider the addition of a second centre to demonstrate 
generalisability and help with recruitment.” 
In one application, funders requested applicants increase homogeneity in treatments and the 
applicants argued against this. 
“To ensure homogeneity in treatments we have consulted with our participating surgeons [and] the 
National […] Registry and agreed to specify the use of a CE marked [device…there are three main 
devices]. Surgical trials that specify a single type of [device] are notoriously difficult to conduct and we 
do not believe such a design could recruit surgeons, nor would the outputs be generalisable. “
Further considerations with regard to surgeon credentials (n=3) and the impact of surgeon equipoise 
on recruitment (n=1) were also funder driven. 
“The sample size has been increased from a total of [n] patients to a total of [1.4n] to take into account 
clustering of surgeon as per the feedback from the first stage.”
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4. CONCLUSIONS
This review has investigated the decision-making behind intended design and analysis of 50 
randomised surgical trials funded by the NIHR EME and NIHR HTA programmes from 2012 to 2016. 
These results show frequent consideration of centres and surgeon impact during design, and these 
may be funder led, due to concerns around homogeneity or generalisability of results. This review 
provides a cross sectional insight into current practice of researchers, and expectations of reviewers 
and funders, during trial design within two streams of a major UK funder. [17, 18] 
The need for transparency around learning curves and clustering are highlighted within reporting of 
non-pharmacological interventions guidelines, [22, 23] and a review of the published literature 
identified a deficiency in adherence to these [16]. In contrast, this review identifies that considerations 
to manage learning and clustering are made, by both researchers and funders, during development of 
trials funded by a prestigious body. For example, 30% of multi-centre and 12% of multi-surgeon 
studies reported a statistical adjustment of these within published manuscripts. This was 43% and 68% 
respectively in this cohort. When randomisation was stratified by centre or surgeon, this was 
accounted for in the analysis in 30% of multi-centre and 40% of multi-surgeon trials in the published 
manuscripts, as oppose to 81% and 60% in this cohort. In drawing this comparison it is important to 
differentiate between the intended audiences. The detail required for a funding application, assessed 
by clinicians and methodologists/statisticians, may exceed that required to communicate results to a 
clinical audience. This demonstrates benefit in exploring unpublished trial documentation to 
understand approaches to trial design and analysis and highlights the need for improvements to 
transparent reporting.
The cohort included successful applications to the NIHR 2012 call for Applied Health in Surgery. [7] 
This call recognised the need to increase research-based evidence in surgery. Applications were 
invited that evaluated technology-driven implanted or implantable medical devices, surgical 
procedures or surgical services. As a clinical trial is typically a major financial investment, [24] 
applicants need to assure funders that their proposal is important, well designed and demonstrates 
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scientific value to add to the current evidence base. Each application undergoes a peer review process, 
where ‘experts’ critically review the trial to ensure standards are met in terms of design, quality, 
feasibility, acceptability and importance of the topic. [17, 18] A strength of this review is the insight 
into the designs proposed to funders, and impact of feedback on subsequently funded studies. 
Whilst the degree of learning and clustering will vary trial-to-trial, many interventions require surgical 
skill in their delivery regardless of whether or not the surgery is the intervention of interest. The impact 
of any potential imbalance in delivery on comparing interventions should be considered at trial outset 
routinely. Early and careful consideration will ensure that procedures are standardised as completely 
as possible such that, in severe cases, the trial team can alleviate any doubts about homogeneity 
raised by the medical community should the trial results be questioned. [12] These results indicate 
funder awareness of this early consideration, with one of the two examples of balancing 
randomisation surgeon following recommendation being in a trial where surgery was not the 
intervention of interest. 
When interpreting these results, it is important to consider the limitations of this review. First, only 
successful applications could be included due to confidentiality constraints. It is therefore not possible 
to determine whether the management of learning and clustering contributes to the success of the 
application. However, given that the application process consists of iterations whereby peer reviewers 
are able to request that researchers address paucities in their application, it is unlikely that a promising 
application, lacking in the appropriate considerations, would be deemed unsuitable for funding 
outright. More likely, researchers would be given the opportunity to make these considerations during 
this iteration process. Second, as part of this iterative review, it is possible that additional discussions 
at the funder board meetings did not make it in to the comments fed back to applicants. This could 
mean that funders raised these issues more frequently than this review suggests. Third, due to the 
nature of the grant application process, the funder impact observed may be in part due to an increased 
awareness of the reviewers involved. Fourth, this work has focussed on a single funding body that 
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primarily supports UK based research. However, trials supported span a wide range of surgical 
specialties and health care conditions and results from this review will be generalisable to other 
funding bodies with a similar peer review process. 
Fundamental to trial design and analysis is understanding the objectives. While considerations relating 
to clustering and learning effects are not widely reported in main trial publications, these results 
indicate both funders and researchers consider these aspects in order to address a specific research 
question. Such issues may have varying relevance depending on the overall design of the trial. A very 
pragmatic study may deliberately include surgeons and centres of all types and have less emphasis on 
expertise and learning, whereas the delivery of the intervention in more explanatory studies is critical 
and requires consideration during design and analysis. Another approach to overcoming these issues 
is to provide quality assurance of the intervention. Early work to develop methods to achieve this have 
been developed and it is expected that this will expand in the future. [25] Furthermore, these results 
provide insight into the promising role of the funder as a driver to improving the, long criticised, 
surgical evidence base. The funder, who has influence over whether or not and how studies are carried 
out and has been suggested as a driver for improving the quality of research during the period of 
growth for surgical trials [3], can play a valuable role in ensuring that future trials do not have the 
same shortfalls as those in the past.
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Supplement A1: Data extraction form
The following details were extracted from eligible funding applications:
SECTION 1: Trial details
1.1. Funding identifier (CATEGORICAL – EME / HTA)
1.2. Trial name (FREETEXT)
1.3. Number of randomized controlled trials in application (NUMBERIC)
1.4. Lead institute region (CATEGORICAL – by COUNTY)
1.5. Funding start year (CATEGORICAL – 2012 / 2013 / 2014 / 2015 / 2016 / 2017)
1.6. Documents available for review
1.6.1. Commissioning brief (BINARY – Yes / No)
1.6.2. Project description (BINARY – Yes / No)
1.6.3. Funder changes (BINARY – Yes / No)
1.6.4. Protocol (BINARY – Yes / No)
SECTION 2: Design details
2.1. Trial design (CATEGORICAL - Cluster / Crossover / Parallel / Factorial / Stepped wedge / N-of-1 / 
Sequential)
2.2. Number of trial arms (NUMERIC)
2.3. Use of pilot or feasibility in design 
2.3.1. Pilot study (BINARY – Yes / No)
2.3.2. Feasibility study (BINARY – Yes / No)
SECTION 3: Intervention of interest
3.1. Nature of surgery delivered (BINARY – As an intervention / As part of patient pathway)
3.2. If surgery delivered in as an intervention, what is the comparator (CATEGORICAL – Surgery / 
Medical / Other)
3.3. If surgery is delivered as intervention and is also a comparator, what is the nature of the surgical 
comparator? (CATEGORICAL – Alternative surgical procedure / Change to a component of the same 
procedure / Same procedure delivered at different time points)
3.4. If surgery is delivered as intervention and is also a comparator, was an expertise based design 
utilised? (CATEGORICAL – Pure: professionals delivering only one intervention / Hybrid: some 
professionals could deliver both)
SECTION 4: Recruitment 
4.1. Number of countries (BINARY – Multiple / Single) 
4.2. Number of centres (BINARY – Multiple / Single)
4.3. Number of surgeons (BINARY – Multiple / Single)
SECTION 5: Randomisation
5.1. Method of randomisation (CATEGORICAL – Dynamic allocation / Block / Simple)
5.1.1. If dynamic allocation, specify (BINARY – Minimisation / Other)
5.2. Allocation ratio (BINARY -  Equal / Unequal)
5.3. Randomisation unit (BINARY – Minimisation Individual / Dyad / OtherCluster)
5.4. Randomisation stratified (BINARY – Yes / No)
5.4.1. If randomisation stratified, stratified by country (BINARY – Yes / No)
5.4.2. If randomisation stratified, stratified by centre (BINARY – Yes / No)
5.4.3. If randomisation stratified, stratified by surgeon (BINARY – Yes / No)
SECTION 6: Centre and surgeon credentials 
6.1. Credentials defined (BINARY – Yes / No, not reported)
6.2. Centre credentials (FREETEXT)
6.3. Surgeon credentials (FREETEXT)
SECTION 7: Outcomes
7.1. Outcomes (FREETEXT)
SECTION 8: Statistical considerations
8.1. Sample size considerations e.g. adjusting for ICC (FREETEXT)
8.2. Planned exploratory analysis e.g. differences in outcome between centres (FREETEXT)
8.3. Formal analysis e.g. adjusting models (FREETEXT)
SECTION 9: Funder led considerations
9.1. Commissioning brief (FREETEXT)
9.2. Funder led changes (FREETEXT)
Figure A1: Flowchart of eligibility
Screened
60
Eligible
49 (82%)
Single RCT
48 (98%)
Two RCTs in one 
application
1 (2%)
Not eligible
11 (18%)
No surgery in 
patient pathway
5 (45%)
Not a randomised 
trial
1 (9%)
Surgery is an 
outcome
4 (36%)
Surgery is an 
eligibility criterion
1 (9%)
Table A1: Trial design details
Item Category n N n/N%
Type Parallel 49 50 98%
Sequential [25] 1 50 2%
Number of trial arms 2 45 50 90%
3 4 50 8%
4 1 50 2%
Both pilot and feasibility 2 50 4%Use of pilot or feasibility study, internal or 
external [230] Pilot only 29 50 58%
       Feasibility only 11 50 22%
No 8 50 16%
Nature of surgery delivered As an intervention 39 50 78%
As part of patient pathway 11 50 22%
If intervention comparator Surgery 21 39 54%
Medical 7 39 18%
Other 11 39 28%
Item Category n N n/N%
             If surgical comparator Alternative surgical procedure 13 21 62%
Change to a component of the same procedure 6 21 29%
Same procedure delivered at a different time point 2 21 10%
Table A2: Recruitment and randomisation 
Item Category n N n/N%
Method of randomisation Dynamic allocation 23 50 46%
    Minimisation 21 23 91%
    Other 2 23 9%
Block 17 50 34%
Not specified 10 50 20%
Allocation ratio Equal 48 50 96%
Unequal 1 50 2%
Not specified 1 50 2%
Randomisation unit Patient 50 50 100%
Randomisation stratified Yes 46 50 92%
No, not specified 4 50 8%
Multiple countries participating Yes 3 50 6%
No 45 50 90%
Not reported 2 50 4%
Item Category n N n/N%
If yes, stratified by country     Yes 1 3 33%
    No 2 3 66%
Multiple centres participating Yes 49 50 98%
No 1 50 2%
Not reported 0 50 .
If yes, stratified by centre     Yes 28 49 57%
    No, justification provided 1 49 2%
    No, by other variables 17 49 35%
    No, not stratified 3 49 6%
Multiple surgeons participating Yes 22 50 44%
No 0 50 .
Not reported 28 50 56%
If yes, stratified by surgeon     Yes 8 22 36%
    No, justification provided 0 22 .
    No, by other variables 13 22 59%
Item Category n N n/N%
    No, not stratified 1 22 5%
         If yes, multicentre study     Yes 21 22 96%
    No 1 22 5%
                  If yes, stratified by          Centre and surgeon 2 21 10%
         Centre, not surgeon 11 21 52%
         Surgeon, not centre 6 21 29%
         Neither centre nor surgeon 2 21 10%
